We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
- Authors
Michlmayr, A; Bachleitner-Hofmann, T; Baumann, S; Marchetti-Deschmann, M; Rech-Weichselbraun, I; Burghuber, C; Pluschnig, U; Bartsch, R; Graf, A; Greil, R; Allmaier, G; Steger, G; Gnant, M; Bergmann, M; Oehler, R
- Abstract
Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction of individual response to treatment remains an unsolved clinical problem. Particularly, administration of an inefficient chemotherapeutic regimen should be avoided. Therefore, a better understanding of the molecular mechanisms underlying response to neoadjuvant chemotherapy is of particular clinical interest. Aim of the present study was to test whether neoadjuvant chemotherapy with epirubicin/docetaxel induces early changes in the plasma proteome of breast cancer patients and whether such changes correlate with response to therapy.
- Publication
British journal of cancer, 2010, Vol 103, Issue 8, p1201
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6605909